1201807-92-2

Basic information

• Product Name: 7-(benzyloxy)-2-(3',4'-bis(benzyloxy)phenyl)-5-hydroxy-4H-chromen-4-one
• Synonyms: 7-(benzyloxy)-2-(3',4'-bis(benzyloxy)phenyl)-5-hydroxy-4H-chromen-4-one
• CAS NO: 1201807-92-2
• Molecular Weight: 556.615
• Mol File: 1201807-92-2.mol

Chemical Properties

• CAS DataBase Reference: 7-(benzyloxy)-2-(3',4'-bis(benzyloxy)phenyl)-5-hydroxy-4H-chromen-4-one(CAS DataBase Reference)
• NIST Chemistry Reference: 7-(benzyloxy)-2-(3',4'-bis(benzyloxy)phenyl)-5-hydroxy-4H-chromen-4-one(1201807-92-2)
• EPA Substance Registry System: 7-(benzyloxy)-2-(3',4'-bis(benzyloxy)phenyl)-5-hydroxy-4H-chromen-4-one(1201807-92-2)

Safety Data

• Hazardous Substances Data: 1201807-92-2(Hazardous Substances Data)

Upstream product

• 491-70-3 2-(3,4-Dihydroxy-phenyl)-5,7-dihydroxy-chromen-4-on 
• 100-39-0 benzyl bromide 

Downstream Products

• 1201808-01-6 7-(benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-4-oxo-4H-chromen-5-yl 4-methylpentanoate 
• 1201807-95-5 7-(benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-4-oxo-4H-chromen-5-yl propionate 
• 1201807-94-4 7-(benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-4-oxo-4H-chromen-5-yl benzoate 
• 1201808-00-5 7-(benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-4-oxo-4H-chromen-5-yl 4-methylbenzoate 
• 1201808-02-7 7-(benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-5-ethoxy-4H-chromen-4-one 
• 1258276-38-8 7-benzyloxy-2-(4-benzyloxy-3-ethoxyphenyl)-5-hydroxy-4H-chromen-4-one 
• 1201807-99-9 7-(benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-4-oxo-4H-chromen-5-yl pentanoate 
• 1201807-93-3 7-(benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-4-oxo-4H-chromen-5-yl acetate 
• 1201807-97-7 7-(benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-4-oxo-4H-chromen-5-yl isobutyrate 
• 1201807-96-6 7-(benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-4-oxo-4H-chromen-5-yl butyrate 
• 1201807-98-8 7-(benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-4-oxo-4H-chromen-5-yl octanoate 
• 1201808-08-3 7-(benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-5-isopentyloxy-4H-chromen-4-one 
• 1201808-29-8 7-benzyloxy-2-(4-benzyloxy-3-(isopentyloxy)phenyl)-5-hydroxy-4H-chromen-4-one 
• 1201808-03-8 7-(benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-5-methoxy-4H-chromen-4-one 

Relevant articles and documents

Hydrogels generated by low-molecular-weight PEGylated luteolin and α-cyclodextrin through self-assembly for 5-fluorouracil delivery

Hydrophobic luteolin (LUT) was conjugated to the oligomeric chain of methoxypoly(ethylene glycol) (mPEG) to form novel amphiphilic mPEG1900-LUT conjugates. Then mPEG1900-LUT, by using its adjacent 3′ and 4′ hydroxyl groups, were asse

The construction of gold hybrid supramolecular hydrogels for doxorubicin delivery

Currently, drug delivery systems with low toxicity and high efficacy are urgently needed to suppress cancer cells. Herein, a non-toxic and biocompatible drug carrier (mPEG-luteolin-AuNPs) was prepared, which was characteristic by SEM, FT-IR, XRD, average particle size, zeta potential and UV-Vis spectra, respectively. Considering that the morphology of supramolecular hydrogel was porous which was good for storage of drugs, a stable supramolecular hydrogel self-assembly formed based on mPEG-luteolin-AuNPs and α-cyclodextrin (α-CD) was reported. Then, supramolecular hydrogel loaded doxorubicin hydrochloride (DOX) and sustained DOX release. Meanwhile, in vitro experiments clearly demonstrated that DOX of hydrogel (mPEG-luteolin-AuNPs/DOX) was biologically active, similar to free DOX, but with better cytotoxicity to human glioblastoma cells (U-87?MG) because of its controllable release. Our findings indicated that mPEG-luteolin-AuNPs/DOX might be promising delivery systems for anticancer chemotherapy.

Discovery and synthesis of novel luteolin derivatives as DAT agonists

Luteolin, 5,7-dihydroxy-2-(3,4-dihydroxyphenyl)-4H-chromen-4-one, has been proposed and proved to be a novel dopamine transporter (DAT) activator. In order to develop this potential of luteolin, a series of novel luteolin derivatives were designed, synthesized, and evaluated for their DAT agonistic activities, utilizing constructed Chinese hamster ovary (CHO) cell lines stably expressing rat DAT. Biological screening results demonstrated that luteolin derivatives 1d, 1e, and 4c carry great DAT agonistic potency (EC50 = 0.046, 0.869, and 1.375 μM, respectively) compared with luteolin 8 (EC50 = 1.45 ± 0.29 μM). Luteolin derivative 1d, notably, exhibited a 32-fold-higher DAT agonistic potency than luteolin. These luteolin derivatives represent a novel DAT agonist class, from which lead compounds useful for exploration of additional novel DAT agonists could be drawn.